SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Proof of Concept Study Initial Findings

[January 28, 2013]

Proof of Concept Study Initial Findings

PERTH, Australia, Jan. 28, 2013 /PRNewswire via COMTEX/ -- Bone Medical Ltd (ASX: BNE), a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic(TM) peptide discovery technology.


These first results confirm that BN006 reduces inflammation in a collagen-antibody induced arthritis disease model, a widely used benchmark for evaluating and comparing novel treatments for RA. The reduction appeared to be dose-related.

Significantly, BN006 achieved notable reduction in inflammation with only a modest reduction of TNF. TNF is one of the body's inflammatory agents that play an important role in the RA disease process. BN006 has also been shown to reduce IL-6, another cytokine involved in RA.

Dr Roger New, CSO and inventor of the Mozaic(TM) system, explained, "The current standard of care for the treatment of RA works by binding to TNF and blocking its activity systemically. This approach reduces TNF's ability to play its role in the body's immune response, leading to the adverse events that most commonly limit the clinical role of these products." "In our study, BN006 achieved its effect with only a small reduction in TNF," continued Dr New. "While adalimumab (Humira(TM)) eliminated inflammation in our study, it almost completely blocked TNF. This provides experimental evidence for BN006's selective mechanism of action, which acts directly on macrophages to reduce their inflammatory activity, and confirms its potential to become an important advance in the treatment for RA." Dr New said the Company was continuing to evaluate the results of the study, and would add another BN006 treatment arm to further expand the study outcomes. More complete results are expected over the next couple of months.

Contact: Dr Roger New Peter Young Chairman CEO +44 207 794 1512 +1 201 841 9681 Leon Ivory Director +61 419 428 264 or visit: www.bone-ltd.com About Bone Medical Limited Bone Medical Limited focuses on developing significant new products for the treatment of bone diseases like osteoarthritis, rheumatoid arthritis, and osteoporosis. The Company's product pipeline includes Phase II clinical-stage programs for the oral delivery of CaPTHymone(TM) (parathyroid hormone) for osteoporosis and Capsitonin(TM) (calcitonin) for osteoarthritis pain and osteoporosis, and novel preclinical-stage compounds like BN006, BN007, a collagen tolerance & joint protection agent for RA, and BN005 & BN008, bone cell regulators for osteoporosis.

SOURCE Bone Medical Ltd

[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy